13,7 % Poblacin Comparacin directa en obesidad Pptido Retatrutida Dosis 12 mg/semana Duracin 48 semanas Reduccin de peso ~24,2 % Poblacin Obesidad, sin diabetes Pptido Retatrutida Dosis Dosis mximas Duracin Fase 3 Reduccin de peso ~28,7 % Poblacin Obesidad + osteoartritis Nota importante: Los valores no son directamente comparables porque las poblaciones y los diseos de los estudios difieren
In addition to the US FDA approved GLP-1RAs, there are GLP1/glucagon dual agonists (Cotadutide, BI 456906), GIP/GLP1 dual agonists (Tirzepatide, GIP/GLP peptide I and II), GIP/GLP1/glucagon tri-agonists (HM15211, GGG tri-agonist) and GLP1R agonists (Efpeglenatide, Rybelsus) currently in phase 1- III clinical trials for T2D, obesity, and NASH (MASH) treatments (12)
Cardiovascular Support L-carnitine's efficacy in heart disease was confirmed by a meta-analysis published recently in the Mayo Clinic Proceedings
The first GLP-1s secured approval as diabetes therapies in 2014, but uptake was slow given that they required daily injections and weight loss was limited
Best for: Individual researchers who want a listed, COA-backed source
Greater Trochanteric Pain Syndrome This condition, previously called trochanteric bursitis, actually involves gluteal tendinopathy more often than pure bursitis